Advanced search
1 file | 475.94 KB Add to list

Short communication: Antimicrobial efficacy of intramammary treatment with a novel biphenomycin compound against Staphylococcus aureus, Streptococcus uberis, and Escherichia coli-induced mouse mastitis

Dieter Demon (UGent) , Koen Breyne (UGent) , Guido Schiffer and Evelyne Meyer (UGent)
(2013) JOURNAL OF DAIRY SCIENCE. 96(11). p.7082-7087
Author
Organization
Abstract
Bovine mastitis undermines udder health, jeopardizes milk production, and entails prohibitive costs, estimated at $2 billion per year in the dairy industry of the United States. Despite intensive research, the dairy industry has not managed to eradicate the 3 major bovine mastitis-inducing pathogens: Staphylococcus aureus, Streptococcus uberis, and Escherichia coli. In this study, the antimicrobial efficacy of a newly formulated biphenomycin compound (AIC102827) was assessed against intramammary Staph. aureus, Strep. uberis, and E. coli infections, using an experimental mouse mastitis model. Based on its effective and protective doses, AIC102827 applied into the mammary gland was most efficient to treat Staph. aureus, but also adequately reduced growth of Strep. uberis or E. coli, indicating its potential as a broad-spectrum candidate to treat staphylococcal, streptococcal, and coliform mastitis in dairy cattle.
Keywords
Escherichia coli, Streptococcus uberis, BOVINE MASTITIS, INFECTION, PATHOGENS, ANTIBIOTICS, SUSCEPTIBILITY, MICE, MODELS, antimicrobial therapy, Staphylococcus aureus, LACTATION

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 475.94 KB

Citation

Please use this url to cite or link to this publication:

MLA
Demon, Dieter et al. “Short Communication: Antimicrobial Efficacy of Intramammary Treatment with a Novel Biphenomycin Compound Against Staphylococcus Aureus, Streptococcus Uberis, and Escherichia Coli-induced Mouse Mastitis.” JOURNAL OF DAIRY SCIENCE 96.11 (2013): 7082–7087. Print.
APA
Demon, D., Breyne, K., Schiffer, G., & Meyer, E. (2013). Short communication: Antimicrobial efficacy of intramammary treatment with a novel biphenomycin compound against Staphylococcus aureus, Streptococcus uberis, and Escherichia coli-induced mouse mastitis. JOURNAL OF DAIRY SCIENCE, 96(11), 7082–7087.
Chicago author-date
Demon, Dieter, Koen Breyne, Guido Schiffer, and Evelyne Meyer. 2013. “Short Communication: Antimicrobial Efficacy of Intramammary Treatment with a Novel Biphenomycin Compound Against Staphylococcus Aureus, Streptococcus Uberis, and Escherichia Coli-induced Mouse Mastitis.” Journal of Dairy Science 96 (11): 7082–7087.
Chicago author-date (all authors)
Demon, Dieter, Koen Breyne, Guido Schiffer, and Evelyne Meyer. 2013. “Short Communication: Antimicrobial Efficacy of Intramammary Treatment with a Novel Biphenomycin Compound Against Staphylococcus Aureus, Streptococcus Uberis, and Escherichia Coli-induced Mouse Mastitis.” Journal of Dairy Science 96 (11): 7082–7087.
Vancouver
1.
Demon D, Breyne K, Schiffer G, Meyer E. Short communication: Antimicrobial efficacy of intramammary treatment with a novel biphenomycin compound against Staphylococcus aureus, Streptococcus uberis, and Escherichia coli-induced mouse mastitis. JOURNAL OF DAIRY SCIENCE. 2013;96(11):7082–7.
IEEE
[1]
D. Demon, K. Breyne, G. Schiffer, and E. Meyer, “Short communication: Antimicrobial efficacy of intramammary treatment with a novel biphenomycin compound against Staphylococcus aureus, Streptococcus uberis, and Escherichia coli-induced mouse mastitis,” JOURNAL OF DAIRY SCIENCE, vol. 96, no. 11, pp. 7082–7087, 2013.
@article{5918796,
  abstract     = {Bovine mastitis undermines udder health, jeopardizes milk production, and entails prohibitive costs, estimated at $2 billion per year in the dairy industry of the United States. Despite intensive research, the dairy industry has not managed to eradicate the 3 major bovine mastitis-inducing pathogens: Staphylococcus aureus, Streptococcus uberis, and Escherichia coli. In this study, the antimicrobial efficacy of a newly formulated biphenomycin compound (AIC102827) was assessed against intramammary Staph. aureus, Strep. uberis, and E. coli infections, using an experimental mouse mastitis model. Based on its effective and protective doses, AIC102827 applied into the mammary gland was most efficient to treat Staph. aureus, but also adequately reduced growth of Strep. uberis or E. coli, indicating its potential as a broad-spectrum candidate to treat staphylococcal, streptococcal, and coliform mastitis in dairy cattle.},
  author       = {Demon, Dieter and Breyne, Koen and Schiffer, Guido and Meyer, Evelyne},
  issn         = {0022-0302},
  journal      = {JOURNAL OF DAIRY SCIENCE},
  keywords     = {Escherichia coli,Streptococcus uberis,BOVINE MASTITIS,INFECTION,PATHOGENS,ANTIBIOTICS,SUSCEPTIBILITY,MICE,MODELS,antimicrobial therapy,Staphylococcus aureus,LACTATION},
  language     = {eng},
  number       = {11},
  pages        = {7082--7087},
  title        = {Short communication: Antimicrobial efficacy of intramammary treatment with a novel biphenomycin compound against Staphylococcus aureus, Streptococcus uberis, and Escherichia coli-induced mouse mastitis},
  url          = {http://dx.doi.org/10.3168/jds.2013-7011},
  volume       = {96},
  year         = {2013},
}

Altmetric
View in Altmetric
Web of Science
Times cited: